• Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Heterozygous (PubMed=9598804).
  
• Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=9598804).
  

PubMed=6976407; DOI=10.1084/jem.154.6.1764
Albino A.P., Lloyd K.O., Houghton A.N., Oettgen H.F., Old L.J.
Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient Implications for the study of tumor antigens.
J. Exp. Med. 154:1764-1778(1981)

PubMed=7017212; DOI=10.1093/jnci/66.6.1003
Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.
HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.
J. Natl. Cancer Inst. 66:1003-1012(1981)

PubMed=6864164; DOI=10.1084/jem.158.1.53
Houghton A.N., Brooks H., Cote R.J., Taormina M.C., Oettgen H.F., Old L.J.
Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma.
J. Exp. Med. 158:53-65(1983)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=2983346; DOI=10.1073/pnas.82.5.1470
Dracopoli N.C., Houghton A.N., Old L.J.
Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogeneity.
Proc. Natl. Acad. Sci. U.S.A. 82:1470-1474(1985)

PubMed=3081645; DOI=10.4049/jimmunol.136.7.2534
Panneerselvam M., Welt S., Old L.J., Vogel C.-W.
A molecular mechanism of complement resistance of human melanoma cells.
J. Immunol. 136:2534-2541(1986)

PubMed=2886213
Dracopoli N.C., Alhadeff B., Houghton A.N., Old L.J.
Loss of heterozygosity at autosomal and X-linked loci during tumor progression in a patient with melanoma.
Cancer Res. 47:3995-4000(1987)

PubMed=1716514
Albino A.P., Davis B.M., Nanus D.M.
Induction of growth factor RNA expression in human malignant melanoma: markers of transformation.
Cancer Res. 51:4815-4820(1991)

PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N
Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C., Fountain J.W.
Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Genes Chromosomes Cancer 22:157-163(1998)